|

Investigator's choice of chemotherapy Clinical Trials

3 actively recruiting trials across 1 location

Also known as: ICC, gemcitabine, paclitaxel, pegylated liposomal doxorubicin (PLD), topotecan

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.1
  • Incyte Corporation1
  • Fudan University1

Indications

  • Cancer3
  • Breast Cancer2
  • Mutation1
  • Metastatic Breast Cancer1
  • Breast Cancer, Metastatic1

Other2 trials

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations
Phase 2
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Phase 3

Duarte, California1 trial

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

City of Hope Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.